DIFFERENTIAL DIAGNOSTICS OF PREECLAMPSIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
https://doi.org/10.24884/1561-6274-2019-23-1-45-50
Abstract
THE AIM: To assess the significance of prognostic markers of preeclampsia – sFlt-1 and PlGF in the differential diagnosis of preeclampsia and chronic kidney disease. PATIENTS AND METHODS: patients whom signed informed consent, was taken samples of blood in the third trimester of pregnancy. The study group included 36 patients with preeclampsia, the comparison group of 46 pregnant women with CKD and the control group included 40 healthy patients, with pregnancy without complication. RESULTS: Significant differences in the levels of serum sFlt-1 and PlGF were found: between the PE and the comparison group (CKD), as well as between the PE and the control group (CG), whereas no differences were found between the CG and CKD. The sFlt-1 level was significantly increased in PE compared with CKD and KG (5.12-fold and 4.25-fold higher, respectively). Serum PlGF levels were significantly reduced in PE relative to both CKD and KG (17.4 and 12.5 times lower, respectively). The sFlt-1/PlGF ratio was significantly increased in PE compared with CKD and the control group (approximately 25 times higher in both groups), but there was no significant difference between CKD and CG. CONCLUSION: Thus, the definition of the relationship sFlt-1, PlGF, sFlt-1/PlGF can be used in the differential diagnosis of preeclampsia and chronic kidney disease.
About the Authors
R. R. Temirbulatov
Department of obstetrics, gynecology and neonatology, Pavlov First Saint Petersburg State Medical University, St.-Petersburg; Clinic of obstetrics and gynecology, Pavlov First Saint Petersburg State Medical University, St.-Petersburg
Russian Federation
Russian Federation
R.R. Temirbulatov, MD
197022, St-Petersburg, L. Tolstoy st., 6-8, build. 4. First Pavlov St.-Petersburg I.P. Pavlov State Medical University, Department of obstetrics, gynecology and neonatology.
Phone: 8(931)2234093
V. F. Bezhenar
Department of obstetrics, gynecology and neonatology, Pavlov First Saint Petersburg State Medical University, St.-Petersburg; Department of obstetrics, gynecology and reproductology, Pavlov First Saint Petersburg State Medical University, St.-Petersburg; Clinic of obstetrics and gynecology, Pavlov First Saint Petersburg State Medical University, St.-Petersburg
Russian Federation
Russian Federation
Vitaliy F. Bezhenar, MD, PhD, DMedSci
197022, St-Petersburg, L. Tolstoy st., 6–8, build. 4. Pavlov First Saint Petersburg State Medical University, head of clinic of obstetrics and gynecology, head of department of obstetrics, gynecology and neonatology, head of department of
obstetrics, gynecology and reproductology.
Phone: (812)3386715
A. V. Smirnov
Research Institute of Nephrology, Scientific and Clinical Research Center, Pavlov First Saint Petersburg State Medical University, St.-Petersburg; Department of Propaedeutics of Internal diseases, Pavlov First Saint Petersburg State Medical University, St.-Petersburg
Russian Federation
Russian Federation
Alexey V. Smirnov, MD, PhD, DMedSci
197022, St-Petersburg, L. Tolstoy st., 17. Pavlov First Saint Petersburg State Medical University, director of the scientific research institute of nephrology, head of department of propaedeutics of internal diseases.
Phone: (812)338-69-01
References
1. Савельева ГМ, Серов ВН, Сухих ГТ. Акушерство и гинекология: Клинические рекомендации. ГЭОТАР-Медиа, М., 2015. 1024 с. [Saveleva GM, Serov VN, Suhih GT. Akusherstvo i ginekologiya: Klinicheskie rekomendacii.: GEHOTAR-Media, М., 2015. 1024 s.]
2. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159–167
3. Williams D, Davison J. Chronic kidney disease in pregnancy. BMJ 2008; 336: 211–215
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–266
5. Vikse BE, Irgens LM, Leivestad T et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800–809
6. Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996; 335: 226–232
7. Murakami S, Saitoh M, Kubo T et al. Renal disease in women with severe preeclampsia or gestational proteinuria. Obstet Gynecol 2000; 96: 945–949
8. Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem 2007; 109: 257–265
9. Huppertz B, Peeters LL. Vascular biology in implantation and placentation. Angiogenesis 2005; 8: 157–167
10. Hung TH, Skepper JN, Burton GJ. In vitro ischemiareperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol 2001; 159: 1031–1043
11. Li H, Gu B, Zhang Y et al. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005; 26: 210–217
12. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998; 8: 588–594
13. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–1136
14. De Vivo A, Baviera G, Giordano D et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837–842
15. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683
16. Verlohren S, Galindo A, Schlembach D et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161 e161–161 e111
Review
For citations:
Temirbulatov R.R., Bezhenar V.F., Smirnov A.V. DIFFERENTIAL DIAGNOSTICS OF PREECLAMPSIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology (Saint-Petersburg). 2019;23(1):45-50. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-1-45-50
Views:
3269
Email this article 